Clinical Trial Update: PCI With AXXESS Biolimus A9 Eluting Bifurcation Stent in Treating Coronary Artery Bifurcation Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the AXXESS Biolimus A9 eluting bifurcation stent for treating coronary bifurcation lesions has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Bifurcation Lesions

Drugs mentioned

• AXXESS Biolimus A9 Eluting Bifurcation Stent

Snippet

Sponsor: Yonsei University | Conditions: Coronary Bifurcation Lesions | Phase 4 | Status: WITHDRAWN